1406873
Last Update Posted: 2018-06-19
Recruiting has ended
All Genders accepted | 18 Years-80 Years |
42 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
The purpose of this study is to investigate the effects of mexiletine treatment for 6 months on ambulation, myotonia, muscle function and strength, pain, gastrointestinal functioning, cardiac conduction, and quality of life in myotonic dystrophy type 1 (DM1).
This study will provide data on the long term (6 months) safety and efficacy of mexiletine in:
- improving the distance participants are able to walk in six minutes;
- reducing myotonia;
- improving muscle strength;
- increasing lean muscle mass;
- decreasing musculoskeletal pain;
- improving gastrointestinal function and swallowing);
- improving functional abilities;
- decreasing cardiac arrhythmias; and
- improving disease-specific health related quality-of-life.
Eligibility
Relevant conditions:
Myotonic Dystrophy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov